Personalized

Cell Therapy

begins with

You.

Spotlight

Chief Scientific Officer Xiaokui Zhang Profiled in Insights Care Magazine

Aspen Neuroscience Featured in the Wall Street Journal

CEO Damien McDevitt, PhD, Featured in Biocom’s Article, “A Look at the Year Ahead for Life Sciences.”

Aspen Neuroscience leverages stem cell biology and genomics for Parkinson disease.

We are the leading company providing a personalized cell therapy with the aim to safely turn the clock back on Parkinson’s disease.

We are leveraging our in-house stem cell biology and genomics platform to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson’s Disease.

Technology

News & Media

Investor Relations

Careers

ABOUT US

Find out about our organization,mission, our leadership team, our board of directors and scientific advisors.

Learn More

OUR PIPELINE

We are developing autologous IPSC-derived cell replacement therapies, including autologous neuron therapies to help treat both idiopathic and genetically linked forms of Parkinson’s disease.

Learn More

Please note that we at Aspen Neuroscience do not make determinations on who would be eligible for participation in clinical trials, and we do not offer tours of our laboratory. At this time, our therapy has not yet been used in humans and clinical trials have not begun.